A first-in-class monoclonal antibody has shown significant reductions in skin disease in patients with cutaneous lupus erythematosus (CLE). Litifilimab met the primary endpoint of reduction of disease ...
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at ...
Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the ...
Both subacute cutaneous lupus and discoid lupus are a form of lupus skin disease, though they have some distinct differences. Subacute cutaneous lupus may show up as ring-shaped red, scaly lesions.
In light of litifilimab recently receiving FDA Breakthrough Therapy Designation for CLE, we spoke with experts to discuss ...
Litifilimab significantly improved skin disease activity in CLE, with a CLASI-A score difference from placebo of up to -33.4 percentage points. The Food and Drug Administration (FDA) has granted ...
Please provide your email address to receive an email when new articles are posted on . Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania Hospital, and chief of ...
Please provide your email address to receive an email when new articles are posted on . CLEVELAND — While new treatments for cutaneous lupus are on the horizon, sunscreen remains the best way to ...
Survey results indicated that cutaneous lupus erythematosus (CLE) significantly affects quality of life (QOL) independently and additively in patients with systemic lupus erythematosus (SLE), with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results